特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
919376

α1アンチトリプシン欠損症 (A1AD):パイプライン製品の分析

Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 118 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
α1アンチトリプシン欠損症 (A1AD):パイプライン製品の分析
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 118 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界各国におけるα1アンチトリプシン欠損症 (A1AD) のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

α1アンチトリプシン欠損症 (A1AD) - 概要

α1アンチトリプシン欠損症 (A1AD) - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

α1アンチトリプシン欠損症 (A1AD) - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

α1アンチトリプシン欠損症 (A1AD) の治療薬開発に従事している企業

  • Adverum Biotechnologies Inc
  • Alnylam Pharmaceuticals Inc
  • Apic Bio Inc
  • Applied Genetic Technologies Corp
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • Beam Therapeutics Inc
  • Editas Medicine Inc
  • Evolve Biologics Inc
  • Grifols SA
  • Inhibrx Inc
  • Intellia Therapeutics Inc
  • International Stem Cell Corp
  • Kamada Ltd
  • LEXEO Therapeutics LLC
  • Liminal BioSciences Inc
  • Logicbio Therapeutics Inc
  • PlantForm Corp
  • Promethera Biosciences SA
  • Renovion Inc
  • Santhera Pharmaceuticals Holding AG
  • Trucode Gene Repair Inc
  • Vertex Pharmaceuticals Inc
  • Z Factor Ltd

α1アンチトリプシン欠損症 (A1AD) - 治療薬の評価

α1アンチトリプシン欠損症 (A1AD) - 休止中のプロジェクト

α1アンチトリプシン欠損症 (A1AD) - 開発が中止された製品

α1アンチトリプシン欠損症 (A1AD) - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Alpha-1 Antitrypsin Deficiency (A1AD), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Alnylam Pharmaceuticals Inc, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Apic Bio Inc, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Applied Genetic Technologies Corp, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects, H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Alpha-1 Antitrypsin Deficiency (A1AD), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12470IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H2 2020, provides an overview of the Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline landscape.

Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline guide also reviews of key players involved in therapeutic development for Alpha-1 Antitrypsin Deficiency (A1AD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1, 16, 3 and 2 respectively.

Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases).
  • The pipeline guide reviews pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Overview
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Therapeutics Development
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Therapeutics Assessment
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Companies Involved in Therapeutics Development
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Drug Profiles
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Discontinued Products
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.